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Objectives. The purpose of this study was to investigate the role
of endothelium-dependent vascular regulation in the human
coronary circulation during rest and hyperemic states.
Background. Evidence of the role of nitric oxide (NO) during
metabolic demand is not consistent in animal and human coro-
nary circulation.
Methods. NG-Monomethyl-L-arginine (L-NMMA), a specific in-
hibitor of NO synthesis, was infused into the left anterior descend-
ing coronary artery at rest and during rapid atrial pacing in 18
subjects—9 with normal coronary arteries (control) and 9 with
atherosclerotic coronary arteries. The diameter of the epicardial
coronary artery was measured by quantitative coronary angiogra-
phy. Vasodilation of the coronary microcirculation was assessed
using an intracoronary Doppler FloWire.
Results. Infusion of 25 mmol/min of L-NMMA reduced the
diameter of the proximal and distal epicardial coronary artery
segments by 8 6 2% (mean 6 SE) and 11 6 2%, respectively (p <
0.05) in the control subjects. The coronary blood flow (CBF)
decreased by 33 6 13% during L-NMMA infusion. L-NMMA
caused similar changes in the diameter of the distal epicardial
segment and the CBF in patients with coronary artery disease.
The proximal vessel diameter did not change significantly during
infusion of L-NMMA. During pacing, infusion of L-NMMA caused
the same changes in vessel diameter as before pacing in both
groups, but did not affect CBF.
Conclusions. Our findings indicate that NO synthesis main-
tains basal vasomotor tone in both conduit and resistance vessels
in the normal human coronary circulation. Although NO release
was impaired in the large epicardial coronary arteries in patients
with atherosclerosis, NO still regulated vascular tone in the small
epicardial coronary arteries and arterioles. Our results suggest
that vasodilation in arterioles during increased myocardial oxy-
gen demand is mediated by metabolic or myogenic mechanisms,
or both, rather than by endothelium-dependent production of NO.
(J Am Coll Cardiol 1997;29:85–92)
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The endothelium modulates many aspects of vascular function,
including vascular growth, anticoagulant, fibrinolytic and anti-
thrombotic properties, permeability and inflammatory and
immune mechanisms in the vessel wall. Endothelial cells
synthesize and release vasodilator substances, collectively re-
ferred to as endothelium-derived relaxing factor into the
lumen and influence the tone of underlying smooth muscle (1).
Endothelium-derived relaxing factor has been identified as
nitric oxide (NO) or related chemical compounds with the
same biologic and pharmacologic properties. Release of a
sufficient amount of NO appears to account for the many
biologic actions of endothelium-derived relaxing factor (2–4).
NG-Monomethyl-L-arginine (L-NMMA), a specific inhibitor of
NO synthesis, inhibits endothelium-dependent relaxation in
vitro (5,6) and increases systemic blood pressure in the rat (7),
rabbit (8) and guinea pig (9) in vivo. Infusion of L-NMMA into
the brachial artery of the human forearm reduced basal blood
flow, and blood flow returned to the basal state after infusion
of L-arginine (10). These findings indicate that NO contributes
to the maintenance of vascular tone and therefore to regula-
tion of tissue blood flow in various species, including humans.
Although evidence indicates that NO is a significant regu-
lator of tissue flow in the systemic circulation, the role of NO
in the regulation of vascular tone in the coronary conductance
and resistance vessels is inconsistent. Woodman and Dusting
(11) showed that the inhibition of NO synthesis reduced the
diameter of the coronary artery without affecting coronary
vascular resistance in an acute anesthetized, canine model,
which suggests that NO modulates basal vasomotion in the
large epicardial coronary arteries but not in the microcircula-
tion. Chu et al. (12,13) found that although L-NMMA reduced
both the diameter of proximal epicardial coronary arteries and
coronary blood flow (CBF) in conscious dogs, its effects on
flow were modest and higher doses of L-NMMA were required
to significantly reduce the diameter of epicardial coronary
arteries. Lefroy et al. (14) found that infusion of L-NMMA into
normal human coronary arteries reduced the diameter of the
distal portion of epicardial coronary arteries and CBF, but not
the diameter of the proximal segments.
The evidence for the role of NO during increased metabolic
demand is less consistent in previous studies. Persson et al.
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(15) found that L-NMMA did not alter the hyperemic response
to exercise in isolated rabbit skeletal muscle. In a chronic
canine model, L-NMMA was reported not to influence the
increase in CBF produced by pacing to ;200 beats/min (16),
whereas Jones et al. (17) showed inhibition of NO-attenuated
coronary dilation during pacing in open chest dogs. The flow
response to L-NMMA in the human forearm during exercise
was unchanged in a study by Wilson and Kapoor (18), but was
reduced in a study by Gilligan et al. (19). Recently, Quyyumi et
al. (20) reported that cardiac pacing produced less microvas-
cular and epicardial coronary artery dilation after L-NMMA,
suggesting that the release of NO contributes significantly to
metabolic vasodilation in the coronary circulation. The dis-
crepancies concerning the role of NO in metabolic vasodilation
in the coronary circulation in these studies may be related to
differences in basal blood flow. Endothelial cells respond to
increases in blood flow through a vessel by increasing NO
production (21,22). Thus, the basal level of flow may affect the
response to L-NMMA. In other words, the response to inhibi-
tion of NO synthesis depends on the flow-dependent, NO-
mediated baseline vasodilation in the vessel. Furthermore,
changes in vasomotion through endothelium-independent
mechanisms triggered by the protocols themselves may modify
the response to L-NMMA.
The purpose of this study was to investigate whether the
vascular tone of conduit and resistance vessels in the human
coronary circulation is mediated by NO in both baseline and
hyperemic states. We evaluated the responses to intracoronary
infusion of L-NMMA before and during rapid atrial pacing in
control subjects and patients with coronary artery disease
(CAD).
Methods
Study group. Control subjects. The control group consisted
of nine patients with angiographically normal coronary arteries
(eight men and one woman; mean age 48 years) who were
being evaluated for atypical chest pain and who had negative
exercise tests (Table 1). Control subjects had normal sinus
rhythm. Patients with hypertension ($160/90 mm Hg), diabe-
tes mellitus or hypercholesterolemia ($220 mg/dl) were ex-
cluded. All control subjects had angiographically normal,
smooth coronary arteries and normal left ventricular angio-
grams.
Patients with CAD. We assessed nine patients (six men and
three women; mean age 59 years) who had angiographic
evidence of coronary atherosclerosis. All patients with CAD
had.50% lumen narrowing of the right coronary artery or the
Abbreviations and Acronyms
AHA 5 American Heart Association
CAD 5 coronary artery disease
CBF 5 coronary blood flow
LAD 5 left anterior descending coronary artery
L-NAME 5 NG-nitro-L-arginine methyl ester
L-NMMA 5 NG-monomethyl-L-arginine
NO 5 nitric oxide
Table 1. Clinical Characteristics and Atherogenic Risk Factors of Control Subjects and Patients With Coronary Artery Disease
No.
Age (yr)/
Gender CAG Findings
BP
(mm Hg)
TC
(mg/dl)
TG
(mg/dl)
FBS
(mg/dl)
Control Subjects
1 56/M Normal 120/75 188 114 98
2 47/M Normal 135/85 145 89 102
3 50/M Normal 125/70 170 122 89
4 52/M Normal 130/85 210 145 107
5 40/F Normal 115/65 188 118 103
6 45/M Normal 120/80 179 137 112
7 45/M Normal 130/80 183 134 87
8 55/M Normal 120/80 168 145 96
9 45/M Normal 110/70 156 96 106
Patients With CAD
1 51/M RCA diffuse sclerosis 130/70 178 137 99
2 72/M Seg 1 (50%) 125/75 188 121 110
3 63/M Seg 2 (50%) 145/80 179 139 89
4 69/M Seg 2 (50%); Seg 9 (99%) 130/70 189 126 102
5 47/F Seg 11 (75%) 125/70 167 99 104
6 59/M Seg 1 (90%), Seg 6 (25%) 135/80 189 110 95
7 59/F Seg 1 (50%) 120/80 201 112 84
8 59/M Seg 7 (25%), Seg 11 (75%) 140/80 178 127 89
9 55/F Seg 1 (25%), Seg 9 (75%) 135/85 204 134 107
BP 5 cuff aortic blood pressure; CAD 5 coronary artery disease; CAG 5 coronary arteriography; F 5 female; FBS 5 fasting blood glucose; M 5 male; RCA 5
right coronary artery; Seg 5 American Heart Association segment number (% diameter reduction); TC 5 total serum cholesterol; TG 5 serum triglycerides.
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left circumflex coronary artery, or both. Patients with hemo-
dynamically significant stenosis of the left anterior descending
coronary artery (LAD) were excluded. None of these patients
showed any ischemic ST-T segment changes on the anterior
chest leads during a treadmill test or any evidence of persistent
or reversible defects in the perfusion area of the LAD on a
thallium exercise test. Written informed consent was obtained
from all patients before cardiac catheterization.
Study protocol. Vasoactive medications, including calcium
channel blockers, angiotensin-converting enzyme inhibitors
and long-acting nitrates, were discontinued at least 24 h before
the study. Diagnostic cardiac catheterization was performed by
the standard percutaneous femoral approach in the fasting
state after premedication with oral diazepam (5 to 10 mg).
After completion of routine diagnostic catheterization, sub-
jects received an additional 5,000 U of heparin administered
intravenously. A steerable Doppler guide wire (FloWire, Car-
diometrics) was introduced through a 6F Judkins catheter and
placed in the proximal LAD. The tip of each FloWire was
preshaped into a mild J curve to ensure stable signals. The
Doppler crystal was placed in the proximal segment of the
LAD. Once strong, stable signals were obtained, the position
of the FloWire was left unchanged. A 5F bipolar pacing
catheter was placed in the right atrium. We used atrial pacing
rather than ventricular pacing because it allows arterial pres-
sure to remain higher, resulting in greater myocardial oxygen
consumption and CBF.
All infusions were administered into the LAD through the
Judkin’s catheter at a rate of 2 ml/min. The CBF velocity was
measured and coronary arteriography was performed after a
2-min infusion of 0.9% physiologic saline solution (baseline
before pacing). For coronary arteriography, 6 to 8 ml of
nonionic contrast material was infused manually for 2 to 3 s. In
a preliminary study, infusion of 0.9% saline had no significant
effect on the diameter of either the proximal (22 6 1%, n 5
5) or distal coronary artery segments (22.9 6 1%, n 5 5).
Rapid atrial pacing was then started, and the heart rate was
increased until atrioventricular conduction block was reached
(149 6 12 beats/min). If the pacing rate caused the systolic
blood pressure to decrease by $10 mm Hg, the heart rate was
allowed to fall to minimize the decrease in systolic blood
pressure. Measurements were again obtained 1 min after
initiation of pacing (baseline during pacing). After discontin-
uation of pacing and confirming that CBF velocity and aortic
blood pressure returned to the state before pacing, L-NMMA
(Wako, Osaka, Japan) was infused at a rate of 10 mmol/min for
4 min. The CBF velocity was measured and coronary angiog-
raphy was performed 2 min after initiation of the L-NMMA
infusion, after which rapid atrial pacing was again initiated.
The CBF velocity was measured and coronary angiography was
performed after 1 min of pacing. The same protocol was
repeated during infusion of L-NMMA at a rate of 25 mmol/min.
We did not administer acetylcholine or nitroprusside deliber-
ately to determine to what extent endothelium-dependent and
-independent vasodilation was impaired. This is because 1)
although the duration of action of both agents is short, several
injections of these agents could modify systemic and coronary
vascular tonus enough to result in a different response to
subsequent L-NMMA infusion; and 2) coronary angiography,
which should be performed after each injection, has the
potential to alter the position of the tip of FloWire, resulting in
changes in flow pattern and flow velocity. We used the same
dose of L-NMMA for intracoronary infusions as in the study by
Lefroy et al. (14).
Data analysis. Quantitative coronary angiography. Coro-
nary angiography was performed using a Hitachi cineangio-
graphic system (Hitachi, Tokyo, Japan). Angiography was
performed in the right anterior oblique view with the LAD
near the isocenter. The angle and position of the image intensifier
were kept constant during the study.
The epicardial vessel diameter was determined quantita-
tively using an automated edge detection analysis system
(Baxter, Tokyo, Japan). An end-diastolic frame from a high
quality angiogram was selected and programmed into the
analyzer and digitized with two- to fourfold magnification. Side
branches of the arteries were used as a reference guide to
assess serial changes in the diameter at the same site of the
coronary artery. Previous studies have shown that there is
significant segmental variation in the responses of the proximal
and distal segments of epicardial coronary arteries to vasoac-
tive stimuli (23,24). We separately analyzed the responses of
the proximal (American Heart Association [AHA] segment 6
or 7) and distal segments (AHA segment 8) of the LAD.
Reproducibility using this quantitative analysis system was very
high, with a mean coefficient of 0.98.
Coronary blood flow velocity. The CBF velocity was mea-
sured using FloWire. Coronary blood flow was estimated from
the product of the time-averaged peak velocity and the cross-
sectional area calculated by p 3 diameter2/4.
Statistics. All hemodynamic data are expressed as the mean
value6 SD. Vessel diameter and CBF are expressed as the mean
value 6 SE. Changes in CBF in response to L-NMMA are
expressed as the percent change compared with the baseline data
at rest before L-NMMA. Two-way repeated-measures analysis of
variance (ANOVA) was used to compare the effects of the two
doses of L-NMMA infusions before and during pacing in each
group (normal subjects and patients with CAD). If ANOVA
indicated a significant differences, a paired t test with an appro-
priate Bonferroni correction was used. Differences in diameter
between before and during pacing were compared with the paired
t test. A nonpaired t test was used for data between normal
subjects and patients with coronary artery disease. A value p ,
0.05 was considered significant.
Results
The procedure was well tolerated by all patients. There
were no episodes of chest pain, undesirable side effects or
ischemic ST-T segment changes on electrocardiograms.
Changes in hemodynamic variables. Intracoronary infu-
sion of L-NMMA caused no significant changes in heart rate,
mean aortic blood pressure or rate-pressure product before or
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during pacing in control subjects or patients with CAD (Table
2). Atrial pacing significantly increased heart rate in both
control subjects and patients with CAD (p , 0.01). Although
the mean aortic blood pressure decreased slightly, by ;4%,
during pacing, the rate-pressure product (heart rate–systolic
pressure product) increased by ;110% during pacing in both
groups.
Changes in coronary artery diameter. Before pacing, infu-
sion of 10 mmol/min of L-NMMA caused no significant change
in the diameter of the proximal segment of the LAD, but
infusion of 25 mmol/min significantly reduced its diameter in
the control subjects by 7.8% (p , 0.05) (Fig. 1, left). Pacing
produced a mean 50% increase in CBF. The diameter of the
proximal segments of the LAD during pacing increased from
4.20 6 0.8 to 4.43 6 0.79 mm (p , 0.01). The diameter during
pacing decreased significantly after infusion of L-NMMA (p ,
0.05). The percent change in diameter of the proximal segment
in response to L-NMMA during pacing was significantly higher
than before pacing (11.2 vs. 7.8% at a dose of 25 mmol/min of
L-NMMA), suggesting that sustained release of NO in the
proximal epicardial coronary arteries is greater during an
increase in myocardial oxygen demand than at baseline.
Before pacing, the diameter of the distal segments de-
creased significantly during L-NMMA infusion in control sub-
jects (p , 0.05) (Fig 1, left). Pacing increased the diameter of
the distal segments of the LAD (from 1.9 6 0.3 to 2.02 6
0.41 mm, p , 0.05). L-NMMA decreased the diameter of the
distal segments during pacing (p , 0.05), the same as before
pacing.
Cardiac pacing did not affect the diameter of the proximal
epicardial segment of the LAD in patients with CAD.
L-NMMA caused no significant change in the diameter of the
Figure 1. Change in diameters of
proximal and distal epicardial coro-
nary artery segments in control sub-
jects with normal coronary arteries
(left) and in patients with CAD
(right) before (circles) and during
rapid pacing (squares). L-NMMA105
10 mmol/min of NG-monomethyl-L-
arginine; L-NMMA255 25 mmol/min.
Table 2. Changes in Hemodynamic Variables
Before Pacing During Pacing
Baseline L-NMMA10 L-NMMA25 Baseline L-NMMA10 L-NMMA25
Control Subjects
HR (beats/min) 59 6 9 60 6 11 59 6 10 128 6 8* 131 6 10* 131 6 10*
AoP (mm Hg) 95 6 7 97 6 8 96 6 9 91 6 7 93 6 8 92 6 9
RPP (mm Hg/min) 6,070 6 1,450 6,120 6 1,550 6,080 6 1,490 11,940 6 1,410* 12,890 6 1,550* 12,450 6 1,590*
Patients With CAD
HR (beats/min) 63 6 12 61 6 10 59 6 10 129 6 8* 131 6 10* 131 6 10*
AoP (mm Hg) 93 6 7 94 6 8 92 6 9 90 6 7 91 6 8 89 6 7
RPP (mm Hg/min) 6,110 6 970 6,120 6 1,020 6,010 6 1,120 11,640 6 1,200* 12,890 6 1,350* 12,070 6 1,290*
*p , 0.01 versus before pacing. Data are presented as mean value 6 SD. AoP 5 mean aortic blood pressure; CAD 5 coronary artery disease; L-NMMA10 and
L-NMMA25 5 NG-monomethyl-L-arginine at 10 and 25 mmol/min, respectively; RPP 5 rate-pressure product.
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proximal segment of the LAD from baseline either before or
during pacing in patients with CAD (Fig. 1, right panel). The
diameter of the distal segment decreased significantly during
L-NMMA infusion before pacing in patients with CAD (p ,
0.05). Pacing increased the diameter of the distal segments
from 1.92 6 0.31 to 2.05 6 0.43 mm (p , 0.05). L-NMMA
decreased the diameter of the distal segments during pacing
(p , 0.05), the same as before pacing. These data clearly
indicate a difference between the response to NO inhibition in
the proximal segment and the distal segment of the coronary
arteries of the patients with CAD. There was no difference in
change in the diameter of the distal segment in response to
L-NMMA in the two groups (p 5 NS), suggesting that tonic
release of NO is not impaired in the distal segment in patients
with CAD.
Changes in coronary blood flow. Figure 2 shows represen-
tative Doppler tracings of flow velocity during L-NMMA
infusion before and during rapid pacing in a control subject.
Before pacing, infusion of both 10 and 25 mmol/min of
L-NMMA significantly reduced the CBF in control subjects
(Fig. 3, left panel). L-NMMA infusion caused no significant
change in the CBF from baseline during pacing. In patients
with CAD, infusion of L-NMMA significantly reduced the CBF
before pacing (Fig. 3, right panel). During pacing, L-NMMA
had no significant effect on the CBF in patients with CAD.
Discussion
In control subjects, infusion of L-NMMA reduced the
diameters of the proximal and distal segments of the epicardial
coronary artery and the blood flow at baseline, indicating that
sustained release of NO from the vascular endothelium regu-
lates the vascular tone of coronary arteries of all sizes, ranging
from arterioles with a diameter of 100 to 200 mm, which mainly
determine coronary vascular resistance, to the epicardial con-
duit vessels. In patients with CAD, inhibition of NO reduced
both the diameter of the distal epicardial coronary artery and
the blood flow without a change in the diameter of the
proximal segments, indicating that even though coronary ath-
erosclerosis was associated with impairment of endothelial NO
production in the large epicardial coronary arteries, NO still
played a role in the regulation of rest vascular tone in the small
epicardial coronary arteries and resistant coronary vessels.
During the hyperemic state induced by rapid pacing, L-NMMA
reduced the diameter of the epicardial coronary artery, but did
Figure 2. Representative tracing of coronary Doppler flow velocity in
the control period (before L-NMMA infusion, upper panel) and after
L-NMMA infusion (25 mmol/min, lower panel) in a control subject with
normal coronary arteries. Intracoronary administration of 25 mmol/
min of L-NMMA caused a decrease in the peak systolic and diastolic
coronary Doppler flow velocities compared with baseline before
pacing. The total velocity integrals (CBF) decreased by 23% in
response to L-NMMA. The drug had no effect on the peak flow velocity
during pacing (lower panel).
Figure 3. Percent change in CBF in
control subjects with normal coro-
nary arteries (left) and in patients
with coronary artery disease (right)
before (circles) and during rapid
pacing (squares). Data were normal-
ized as percent from data at baseline
before L-NMMA. L-NMMA10 5 10
mmol/min of NG-monomethyl-L-
arginine; L-NMMA25 5 25 mmol/
min.
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not affect the CBF. Thus, we conclude that NO did not
regulate vascular resistance when myocardial blood flow was
increased by rapid pacing.
Lefroy et al. (14), who first reported the effects of L-NMMA
on human coronary arteries, showed that infusion of 25
mmol/min of L-NMMA caused a significant reduction in the
diameter of the distal segment (5.9%), but not the proximal
segment, of the LAD. One possible explanation for the differ-
ence in the response of the proximal segment of the epicardial
coronary artery to L-NMMA is that their (14) group of patients
may have had more atherosclerotic lesions than did our control
subjects. The control subjects in the present study were about
10 years younger than those in the study by Lefroy et al. (14).
There is evidence that coronary atherosclerosis impairs endo-
thelial cell function (25–27). El-Tamimi et al. (28) showed that
the endothelium-dependent dilator acetylcholine induced both
dilation and constriction in adjacent segments of the same
coronary artery with angiographically minimal atherosclerosis
(22), suggesting that even a minor difference in the degree of
atherosclerosis may have a significant effect on NO production
by endothelial cells and that the severity of endothelial dys-
function is not uniform in the same coronary artery. Chu et al.
(13) found that systemic infusion of L-NMMA reduced the
diameter of the proximal epicardial coronary artery by 8% in
conscious dogs, which is consistent with our hypothesis. The
pathologic changes associated with coronary atherosclerosis
should be less severe in dogs than in humans.
Although NG-nitro-L-arginine methyl ester (L-NAME), an-
other inhibitor of NO production, did not alter the rest CBF in
conscious dogs (16), other studies have found that the rest
regional blood flow decreases after L-NMMA administration.
L-NMMA reduced the rest blood flow in the human forearm by
25% to 50% (10,18,19), the CBF velocity in chronic canine
model by 18% (12) and the CBF calculated by oximetry in
humans by 6% (14). In the present study, the CBF decreased
by 11% after infusion of 25 mmol/min of L-NMMA in rest
control subjects. Our data confirm the hypothesis that NO
synthesis contributes substantially to rest vasomotion in the
human coronary microcirculation.
An important potential influence on the response to NO
inhibition is a basal level of NO activity. An increase in CBF
increases the shear stress, stimulating production of NO in
endothelial cells associated with coronary vasodilation (21,22).
In the present study, the percent change in the proximal LAD
in response to L-NMMA was greater during pacing than before
pacing in control subjects (Fig. 1), supporting the hypothesis
that elevated basal NO activity may be associated with an
enhanced response to L-NMMA. Infusion of L-NMMA before
and during pacing did not affect the proximal segment of the
epicardial coronary artery in the patients with CAD, indicating
that even in a high flow state, atherosclerotic proximal vessels
did not have the ability to produce NO in response to increases
in shear stress—in other words, the ability of endothelial cells
to act as flow sensors, adjusting the diameter to changes in
regional flow, was severely impaired in patients with CAD.
Effects of L-NMMA on the coronary arteries of patients
with CAD. Zeiher et al. (29) found that the pathophysiologic
manifestations of atherosclerosis extend to the coronary mi-
crocirculation: patients with evidence of epicardial atheroscle-
rosis exhibited profound impairment of the ability to increase
blood flow in response to acetylcholine. A decrease in blood
flow after L-NMMA in patients with CAD in the present study
does not contradict the findings of Zeiher et al. (29). Although
the flow response to acetylcholine represents the receptor-
stimulated dilator capacity of vessels mediated by NO, the
vasomotor response to L-NMMA reflects the level of sustained
release of NO by endothelial cells. Thus, the ability of endo-
thelial cells to increase production of NO in response to
several stimulants, such as acetylcholine, bradykinin, substance
P (30,31) and increases in shear stress (21,22), is a separate
phenomenon from the baseline release of NO. The present
data indicate that the ability to produce NO in the rest state is
preserved in both the small epicardial vessels and the micro-
circulation of coronary arteries in patients with CAD, despite
the fact that atherosclerosis impairs the endothelial function of
the large epicardial vessels. These findings are consistent with
previous data, in that the proximal segment is more prone to
atherosclerosis and endothelial dysfunction evaluated from the
response to acetylcholine in patients with angiographically
normal coronary arteries (31).
Effects of L-NMMA on coronary arteries during pacing.
Although NO plays a significant role in the regulation of basal
vasomotion, previous data in animal (15–17) and human
studies (18–20) have shown inconsistent results concerning the
effects of NO inhibition on metabolic vasodilation. Our data
suggest that the release of NO is not an important factor in
pacing-induced arteriolar dilation in the human coronary
circulation.
Gilligan et al. (19) have shown that inhibition of NO syn-
thesis reduces exercise-induced vasodilation in the human
forearm. However, they did not present any data indicating
that vascular resistance and blood flow after termination of
control exercise (before L-NMMA infusion) returned to the
rest value. If any vessel-constricting factors persisted during
exercise after L-NMMA, this could have resulted in the smaller
decrease in vascular resistance during exercise after L-NMMA
than before L-NMMA. Thus, this could lead us to incorrectly
conclude that NO plays a role in exercise-induced vasodilation.
A recent report by Quyyumi et al. (20) has shown evidence of
a significant role of NO in coronary microvascular and epicar-
dial vasodilation in humans. This study also lacks data indicat-
ing that all of the hemodynamic variables and CBF returned to
baseline levels. These investigators performed several infu-
sions of acetylcholine, sodium nitroprusside and adenosine
before L-NMMA infusion, which may have affected coronary
vascular tone. In the present study, we simplified the protocol
to exclude the possible effects of various vasoactive agents on
coronary vascular tone and to minimize the effects of frequent
infusion of coronary angiographic contrast material on the
position of the tip of the FloWire. The present study clearly
demonstrates that coronary flow autoregulation in response to
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metabolic flow recruitment during rapid pacing is mediated by
myogenic or metabolic mechanisms, rather than by a flow-
mediated, endothelium-dependent pathway through NO pro-
duction. Although numerous metabolic factors, including
adenosine, lactate, hypoxia, phosphate, potassium, osmolarity
and prostaglandins (32), have been implicated in the regula-
tion of CBF, the precise role of these mediators remains
controversial. More than one factor is probably involved, so
that even if one of the mediators is blocked, other mediators
are able to compensate for its absence.
Study limitations. There are several potential limitations
to the present study. First, although we paced the heart to
obtain the maximal increase in the heart rate–systolic pressure
product, the increase in flow during pacing was ;40% to 50%.
It is possible that the contribution of NO to metabolic vasodi-
lation may be more important when there is a greater increase
in CBF and therefore a greater increase in the shear stress on
endothelial cells, which stimulates NO production (21,22).
Thus, we cannot rule out the possibility that because of the
modest increase in metabolic demand in the present study,
metabolic or myogenic vasodilation, or both, in the coronary
microcirculation may have overcome NO-mediated vasodila-
tion. However, Wilson and Kapoor (18) found that L-NMMA
did not inhibit the five- to sixfold exercise-induced increase in
the flow response in the forearm, suggesting that even at higher
flow rates, mediators other than NO regulate flow recruitment
during hyperemic conditions.
The heart rate during pacing in this study was a little less
than that in the study of Quyyumi et al. (20) (128 vs. 141
beats/min). However, we adjusted the pacing heart rate to
minimize the decrease in systolic blood pressure, resulting in a
similar increase in CBF to Quyyumi’s study. Thus, the small
difference in pacing heart rate cannot explain the different
response of blood flow to L-NMMA in the two studies.
The dose of L-NMMA used in the present study was lower
than that in Quyyumi’s study. Thus, a possible explanation for
the discrepancy in response to pacing-induced vasodilation in
resistant vessels may simply be the incomplete inhibition of
NO production. Generally, we cannot determine whether
complete inhibition of NO synthesis occurs in resistant vessels
by injection of acetylcholine, because acetylcholine may act on
resistant vessels through the release of vasoactive substances
other than NO from the endocardium, such as adenosine and
endothelium-derived hyperpolarizing factor (33). It is unlikely
that an insufficient dose of L-NMMA could modify blood flow
data in our study. First, the dose of L-NMMA we used has been
shown to inhibit NO production completely in the epicardial
coronary arteries (14), and there has been no evidence indi-
cating that activity of NO synthetase is significantly different
between conductance and resistant vessels. Second, consider-
ing that Japanese patients have a smaller perfusion territory of
the LAD compared with white or black patients (the mean
body weight of our patients was ,60 kg for men and 45 kg for
women), the difference in concentration of L-NMMA in the
heart should be smaller. Our data strongly support the view
that NO has a minor role in pacing-induced vasodilation of
coronary resistant vessels.
Previous studies have shown inconsistent results with re-
gard to the role of NO in metabolic vasodilation. The discrep-
ancies appear not to be due to different doses of L-NMMA or
L-NAME, but to the effects of various interventions performed
in the protocols that could have changed the vasotone of the
vessels, resulting in the different responses to inhibition of NO
production.
During ischemia, endothelium-dependent NO is one of the
important mediators responsible for minimizing coronary vas-
cular resistance (16,34), suggesting that in the presence of
myocardial ischemia, when other vasodilating factors may be
depleted, endothelial vasodilation by NO may be a more
important mechanism of increased tissue perfusion than under
nonischemic conditions. Therefore, although we did not ob-
serve any significant changes in myocardial blood flow in
response to L-NMMA during pacing, blockade of NO synthesis
may worsen the oxygen supply-demand relation in the pres-
ence of critical epicardial stenosis and increased metabolic
demands.
Conclusions. The present findings show that sustained
release of NO played a role in the control of rest vascular tone
in epicardial coronary conduit and resistance vessels in pa-
tients with normal coronary arteries. In patients with CAD,
basal synthesis of endothelial NO was unimpaired in the
coronary circulation, except in the large epicardial coronary
artery, in which administration of L-NMMA had no effect on
the rest vasomotor tone. Inhibition of NO synthesis did not
affect coronary resistance vessel tone when the myocardial
blood flow was increased during rapid pacing, suggesting that
CBF autoregulation in response to metabolic flow recruitment
during pacing is mediated by myogenic or metabolic mecha-
nisms, rather than by endothelium-dependent production of
NO.
We thank the nursing and technical staff of the Cardiac Catheterization
Laboratory at Ichikawa General Hospital for their expert help in conducting this
study.
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